NRG Oncology/RTOG 0926: Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging

D.M Dahl,J Rodgers,W.U Shipley,D Michaelson,C.L Wu,W Parker,J.A Efstathiou,A Jani,F Cury,R Hudes,J.M Michalski,A.C Hartford,D Song,D.E Citrin,T.G Karrison,F.Y Feng

doi:10.1016/j.ijrobp.2021.07.302

NRG Oncology/RTOG 0926: Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging

D.M Dahl, J Rodgers + Show 14 more

Open Access

https://doi.org/10.1016/j.ijrobp.2021.07.302

Copy DOI

Journal: International Journal of Radiation Oncology, Biology, Physics	Publication Date: Oct 22, 2021
Citations: 8

Affiliation: Massachusetts General Hospital, NRG Oncology, McGill University Health Centre, Emory University, St. Agnes Hospital, Johns Hopkins Medicine, Johns Hopkins University, University of California, San Francisco

#Urothelial Cancer Of The Bladder #Bladder Preservation Therapy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

NRG Oncology/RTOG 0926: Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging

Full Text